Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia.
BACKGROUND The effects of statin therapy on the production of monocyte pro-inflammatory cytokines , cardiac function and the long-term prognosis in chronic heart failure ( CHF ) patients with dyslipidemia remain unclear . METHODS AND RESULTS A total of 146 CHF patients with a mean left ventricular ejection fraction ( LVEF ) of 26.9 ± 6.6 % were divided into 2 groups based on whether or not statins were included in their treatment : a statin group ( n=63 ) and a no statin group ( n=83 ) . Only patients with dyslipidemia were treated with statins . Peripheral blood mononuclear cells ( P BMC s ) were isolated , and the production of monocyte tumor necrosis factor (TNF)-α and interleukin (IL)-6 were measured at baseline and after 6 months of treatment , and the data expressed as mean ± SD ( pg·ml(-1)·10(-6 ) P BMC s ) . The LVEF in the statin group improved , and the monocyte TNF-α and IL-6 production decreased ( respectively , P<0.001 ) , but the LVEF and cytokine production remained unchanged in the no statin group . Multivariate Cox hazard analysis showed that statin therapy ( hazard ratio , 0.14 ; 95 % confidence interval : 0.02 - 0.97 , P=0.046 ) was an independent predictor of cardiac events . CONCLUSIONS Statin therapy attenuates the production of monocyte pro-inflammatory cytokines , and ameliorates the cardiac function and may improve long-term prognosis in CHF patients with dyslipidemia
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .